振東製藥(300158.SZ):國通信託-紫金11號集合資金信託計劃延期半年
格隆匯12月17日丨振東製藥(300158.SZ)公佈,公司參與“國通信託-紫金11號集合資金信託計劃”(以下簡稱“紫金11號信託計劃”)的全體持有人於2019年12月17日簽訂了紫金11號信託計劃信託合同補充協議。
公司於2019年1月7日發佈《關於公司部分董事、監事和高管增持公司股份計劃實施完成的公告》,紫金11號信託計劃實施完成,紫金11號信託計劃通過深圳證券交易所交易系統累計增持公司股票1297.52萬股,佔公司目前總股本的1.2560%,交易金額合計4949.99萬元。
紫金11號信託計劃存續期預計12個月,自2018年12月21日至2019年12月20日止,截至本公告日,紫金11號信託計劃持有公司股份1297.52萬股,佔公司目前總股本的1.2560%。
基於對公司未來持續穩定發展的信心及公司股票價值的判斷,同時為了維護紫金11號信託計劃持有人的利益,參與紫金11號信託計劃的全體持有人一致同意將紫金11號信託計劃延期,即存續期在原定終止日的基礎上延長半年,至2020年6月21日。在存續期內,若紫金11號信託計劃所持有的公司股票全部出售,紫金11號信託計劃可提前終止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.